Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients With Type 2 Diabetes

August 8, 2017. This study evaluated whether the sodium-glucose cotransporter-2 (SGLT-2) dapagliflozin improved beta-cell incretin sensitivity by reducing glucotoxicity. In this 3-hour hyperglycemic clamp study, synthetic glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were infused to 19 subjects with type 2 diabetes (T2D) and 10 with normal glucose tolerance (NGT). Subjects with T2D were evaluated twice—before and 8 weeks after treatment with dapagliflozin; subjects with NGT were evaluated once. In patients with T2D, insulin response to GLP-1 and GIP/GLP-1 significantly increased following dapagliflozin use, as did C-peptide response to GLP-1 and first-phase C-peptide response (which is a marker of beta-cell function). All improved values in T2D subjects were lower than NGT subjects. Investigators concluded that, in this study setting, dapagliflozin improved beta-cell response to incretin hormones and glucose. Read the study abstract here.